TP53 mutations in ER+/HER2− breast cancers are known to be associated with poor prognosis and resistance to endocrine therapy [37], and TP53-mutated tumours more frequently have high Oncotype DX recurrence score results than wild-type tumours [38]. Here, ESR1 is linked to breast cancer.